Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia.
Sawyers
C L
CL
Department of Medicine, Division of Hematology and Oncology, Molecular Biology Institute, University of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases